Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

101. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG (...) ) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients, who were or were not receiving statin therapy. Study types included first-line trials in statin-naive/wash-out patients and second-line add-on and uptitration studies in patients on stable statin therapy. Similar analyses of FSG changes were performed separately for each study type in patients who were

Full Text available with Trip Pro

2016 EvidenceUpdates

102. Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial (PubMed)

Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial Simple nudges such as reminders and feedback reports to either a patient or a partner may facilitate improved medication adherence.To test the impact of a pill bottle used to monitor adherence, deliver a daily alarm, and generate weekly medication adherence feedback reports on statin adherence.Three-month, three-arm randomized clinical trial (ClinicalTrials.gov identifier: NCT02480530).One (...) and = 0.001). At 6 months, there was no difference in medication adherence between either of the feedback groups and the control (individual feedback 60 %, partner feedback 52 %, control group 54 %; p = 0.75 and 0.97).Daily alarms combined with individual or partner feedback reports improved statin medication adherence. While neither an individual feedback nor partner feedback strategy created a sustainable medication adherence habit, the intervention itself is relatively easy to implement and low cost.

Full Text available with Trip Pro

2016 EvidenceUpdates

103. PCSK9 Inhibitors: Who Could Need More than a Statin?

PCSK9 Inhibitors: Who Could Need More than a Statin? PCSK9 Inhibitors: Who Could Need More than a Statin? – Clinical Correlations Search PCSK9 Inhibitors: Who Could Need More than a Statin? October 5, 2016 5 min read By Rhodes Hambrick Peer Reviewed The atherosclerotic cardiovascular disease (ASCVD) risk associated with hyperlipidemia (HLD), readily of the mid-20 th century, has been the target of innumerable attempted pharmacologic interventions ever since. One class of agents, the HMG-CoA (...) reductase inhibitors, or statins, became – and have remained 2 – the gold standard for managing HLD-associated ASCVD risk in the setting of the remarkably favorable findings of multiple studies in the 1990s. 3-5 While other agents, including niacin, fish oil, and fibrates, have been demonstrated to have favorable effects on some combination of LDL, HDL, and triglycerides, only statins have been conclusively proven to be of consistent, predictable benefit in reducing ASCVD-related morbidity and mortality

2016 Clinical Correlations

104. Statin withdrawal in people with dementia. (PubMed)

Statin withdrawal in people with dementia. There are approximately 24 million people worldwide with dementia; this is likely to increase to 81 million by 2040. Dementia is a progressive condition, and usually leads to death eight to ten years after first symptoms. End-of-life care should emphasise treatments that optimise quality of life and physicians should minimise unnecessary or non-beneficial interventions. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (...) ; they have become the cornerstone of pharmacotherapy for the management of hypercholesterolaemia but their ability to provide benefit is unclear in the last weeks or months of life. Withdrawal of statins may improve quality of life in people with advanced dementia, as they will not be subjected to unnecessary polypharmacy or side effects. However, they may help to prevent further vascular events in people of advanced age who are at high risk of such events.To evaluate the effects of withdrawal

Full Text available with Trip Pro

2016 Cochrane

105. Interpretation of the evidence for the efficacy and safety of statin therapy. (PubMed)

Interpretation of the evidence for the efficacy and safety of statin therapy. This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect (...) a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend

Full Text available with Trip Pro

2016 Lancet

106. Statins for aortic valve stenosis. (PubMed)

Statins for aortic valve stenosis. Aortic valve stenosis is the most common type of valvular heart disease in the USA and Europe. Aortic valve stenosis is considered similar to atherosclerotic disease. Some studies have evaluated statins for aortic valve stenosis.To evaluate the effectiveness and safety of statins in aortic valve stenosis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS - IBECS, Web of Science and CINAHL Plus. These databases (...) were searched from their inception to 24 November 2015. We also searched trials in registers for ongoing trials. We used no language restrictions.Randomised controlled clinical trials (RCTs) comparing statins alone or in association with other systemic drugs to reduce cholesterol levels versus placebo or usual care.Primary outcomes were severity of aortic valve stenosis (evaluated by echocardiographic criteria: mean pressure gradient, valve area and aortic jet velocity), freedom from valve

Full Text available with Trip Pro

2016 Cochrane

107. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study (PubMed)

A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend primary prevention with statins for individuals with ≥7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD). Everyone living long enough will become eligible for risk-based statin therapy due to age alone.This study sought to personalize ACC/AHA risk-based (...) statin eligibility using noninvasive assessment of subclinical atherosclerosis.In 5,805 BioImage participants without known ASCVD at baseline, those with ≥7.5% 10-year ASCVD risk were down-classified from statin eligible to ineligible if imaging revealed no coronary artery calcium (CAC) or carotid plaque burden (cPB). Intermediate-risk individuals were up-classified from optional to clear statin eligibility if CAC was ≥100 (or equivalent cPB).At a median follow-up of 2.7 years, 91 patients had

Full Text available with Trip Pro

2016 EvidenceUpdates

108. Statin Use and Survival After Acute Kidney Injury (PubMed)

Statin Use and Survival After Acute Kidney Injury The incidence of acute kidney injury (AKI) in hospitalized patients is rising, and survivors are at high risk for cardiovascular events and mortality. Effective strategies that improve long-term outcomes of AKI are unknown.A retrospective cohort study was performed between 2008 and 2011. All subjects were followed until 31 March 2013, with a minimum follow-up of 2 years. Participants were adults 18 years of age or older, who developed AKI (...) during a hospitalization and had chronic kidney disease (CKD) following discharge (n = 19,707 mean age 69.9 years, mean postdischarge estimated glomerular filtration rate (eGFR) 43.0 ml/min/1.73 m2). Exposure to statins was examined prior to the index hospitalization as well as within 2 years following hospital discharge. The primary outcome was mortality; secondary outcomes included all-cause re-hospitalization and cardiovascular events.Within 2 years of discharge, only 38.3% of the participants

Full Text available with Trip Pro

2016 Kidney international reports

109. Does co-enzyme Q10 reduce statin-related muscle pain?

Does co-enzyme Q10 reduce statin-related muscle pain? Does co-enzyme Q10 reduce statin-related muscle pain? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2016\/08\/mo-aug2016cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Aug 08 2016 Does co-enzyme Q10 reduce statin-related muscle pain (...) ? By in , , , , , Journal reference: Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015 Jan;90(1):24-34. Link: Published: January 2015 Evidence cookie says… The effect of CoQ10 on muscle pain in people on statin therapy is uncertain. The research evidence is of limited quality and inconsistent. The range of best estimates includes no effect. CoQ10 cannot be recommended as a matter of routine supplementation

2016 Morsels of Evidence

110. Statins for age-related macular degeneration. (PubMed)

Statins for age-related macular degeneration. Age-related macular degeneration (AMD) is a progressive, late-onset disorder of the macula affecting central vision. It is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown that AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.The objective of this review (...) was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to March 2016), EMBASE (January 1980 to March 2016), Latin American and Caribbean Health

Full Text available with Trip Pro

2016 Cochrane

111. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. (PubMed)

Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. Inflammation may contribute to pathological associations among obesity, diabetes mellitus, and cardiovascular disease.To determine whether targeting inflammation using salsalate compared with placebo reduces progression of noncalcified coronary artery plaque.In the Targeting Inflammation Using Salsalate in Cardiovascular (...) Disease (TINSAL-CVD) trial participants were randomly assigned between September 23, 2008, and July 5, 2012, to 30 months of salsalate or placebo in addition to standard, guideline-based therapies. Randomization was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease.Salsalate (3.5 g/d) or placebo orally over 30

Full Text available with Trip Pro

2016 JAMA cardiology

112. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. (PubMed)

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.  To estimate rates of discontinuation and restarting of statins, and to identify patient characteristics associated with either discontinuation or restarting. Prospective open cohort study. 664 general practices contributing to the Clinical Practice Research Datalink in the United Kingdom. Data extracted in October 2014. Incident statin users aged 25-84 years identified (...) between January 2002 and September 2013. Patients with statin prescriptions divided into two groups: primary prevention and secondary prevention (those already diagnosed with cardiovascular disease). Patients with statin prescriptions in the 12 months before study entry were excluded. Discontinuation of statin treatment (first 90 day gap after the estimated end date of a statin prescription), and restarting statin treatment for those who discontinued (defined as any subsequent prescription between

Full Text available with Trip Pro

2016 BMJ

113. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. (PubMed)

Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data.  To quantify how a period of intense media coverage of controversy over the risk:benefit balance of statins affected their use. Interrupted time series analysis of prospectively collected electronic data from primary care. Clinical Practice Research Datalink (CPRD) in the United Kingdom. Patients newly eligible for or currently taking statins for primary and secondary (...) cardiovascular disease prevention in each month in January 2011-March 2015. Adjusted odds ratios for starting/stopping taking statins after the media coverage (October 2013-March 2014). There was no evidence that the period of high media coverage was associated with changes in statin initiation among patients with a high recorded risk score for cardiovascular disease (primary prevention) or a recent cardiovascular event (secondary prevention) (odds ratio 0.99 (95% confidence interval 0.87 to 1.13; P=0.92

Full Text available with Trip Pro

2016 BMJ

114. Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies. (PubMed)

Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies. Statins are widely prescribed drugs for lowering cholesterol. Some studies have suggested that statins can prevent breast cancer recurrence and reduce mortality rate. However they are not conclusive. Present systematic review and meta-analysis of published cohort studies was conducted to determine the effects of statins intake and risk of breast cancer recurrence (...) and mortality rate.Online databases (PubMed, Embase, Scopus, EBSCO and Cochrane Collaboration) were searched through October 2014. Pooled relative risks and 95 % confidence intervals were calculated with random-effects.A total of 8 cohort studies (4 for recurrence 2 for mortality and 2 for both) involving 124669 participants with breast cancer were eligible. Our results suggest a significant reduction in recurrence (OR= 0.79. I2= 38%) and death (OR = 0.84, I2 = 8.58 %) among statin users.Our meta-analysis

Full Text available with Trip Pro

2016 Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques

115. PCSK9 Inhibitors for Statin Intolerance? (PubMed)

PCSK9 Inhibitors for Statin Intolerance? 27039138 2016 05 02 2018 12 02 1538-3598 315 15 2016 Apr 19 JAMA JAMA PCSK9 Inhibitors for Statin Intolerance? 1571-2 10.1001/jama.2016.3670 Waters David D DD Division of Cardiology, San Francisco General Hospital, San Francisco, California2Department of Medicine, University of California-San Francisco. Hsue Priscilla Y PY Division of Cardiology, San Francisco General Hospital, San Francisco, California2Department of Medicine, University of California

Full Text available with Trip Pro

2016 JAMA

116. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. (PubMed)

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Muscle-related statin intolerance is reported by 5% to 20% of patients.To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab.Two-stage randomized clinical trial including 511 adult patients with uncontrolled low-density lipoprotein cholesterol (...) (LDL-C) levels and history of intolerance to 2 or more statins enrolled in 2013 and 2014 globally. Phase A used a 24-week crossover procedure with atorvastatin or placebo to identify patients having symptoms only with atorvastatin but not placebo. In phase B, after a 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.Phase A: atorvastatin (20 mg) vs placebo. Phase B: randomization 2:1 to subcutaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).Coprimary

Full Text available with Trip Pro

2016 JAMA

117. More HOPE for Prevention with Statins. (PubMed)

More HOPE for Prevention with Statins. 27039666 2016 06 14 2018 12 02 1533-4406 374 21 2016 May 26 The New England journal of medicine N. Engl. J. Med. More HOPE for Prevention with Statins. 2085-7 10.1056/NEJMe1603504 Cushman William C WC From the Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN (W.C.C.); and the Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora (D.C.G.). Goff David C DC Jr From the Preventive Medicine Section

2016 NEJM

118. Statin-Associated Autoimmune Myopathy. (PubMed)

Statin-Associated Autoimmune Myopathy. 26886523 2016 03 01 2016 02 18 1533-4406 374 7 2016 Feb 18 The New England journal of medicine N. Engl. J. Med. Statin-Associated Autoimmune Myopathy. 664-9 10.1056/NEJMra1515161 Mammen Andrew L AL eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Glucocorticoids 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors VB0R961HZT Prednisone AIM IM Algorithms Autoimmune Diseases chemically induced drug therapy Glucocorticoids therapeutic use

2016 NEJM

119. Statins for the prevention of dementia. (PubMed)

Statins for the prevention of dementia. This is an update of a Cochrane review first published in 2001 and then updated in 2009. Vascular risk factors including high cholesterol levels increase the risk of dementia due to Alzheimer's disease and of vascular dementia. Some observational studies have suggested an association between statin use and lowered incidence of dementia.To evaluate the efficacy and safety of statins for the prevention of dementia in people at risk of dementia due (...) to their age and to determine whether the efficacy and safety of statins for this purpose depends on cholesterol level, apolipoprotein E (ApoE) genotype or cognitive level.We searched ALOIS (the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group), The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, ClinicalTrials.gov and the World Health Organization (WHO) Portal on 11 November 2015.We included double-blind, randomised, placebo-controlled trials in which statins were

Full Text available with Trip Pro

2016 Cochrane

120. Risk of Congenital Malformations With Statin Therapy During the First Trimester of Pregnancy

Risk of Congenital Malformations With Statin Therapy During the First Trimester of Pregnancy "Risk of Congenital Malformations With Statin Therapy During the First " by Alexander E. Hoffman < > > > > > Title Author Date of Graduation Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Brent Norris, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background Statins are the most common and effective drug (...) used to treat hyperlipidemia. Based on animal studies showing potential teratogenic effects at high doses, statins are contraindicated in pregnancy due to concern that they would disrupt cholesterol biosynthesis for the fetus. This review evaluates the current evidence of harm caused by statins when taken within the first trimester of pregnancy. Methods An exhaustive literature search was conducted in June 2015 using MEDLINE-Ovid, CINAHL, Evidence-Based Medicine Reviews Multifile, and Web

2016 Pacific University EBM Capstone Project